Ongoing Research on Targeted Therapy in Relapsed/Refractory CLL

This is a video synopsis/summary of an Insights featuring: Nicole Lamanna, MD.

In this segment, Dr. Lamanna discusses updated data at the 2023 American Society of Hematology (ASH) annual meeting from the BRUIN study of the non-covalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib for patients with chronic lymphocytic leukemia (CLL) who progressed after prior covalent BTK inhibitors and sometimes B-cell lymphoma 2 (BCL2) inhibitors as well.

With over 30 months of follow-up, the median progression-free survival with pirtobrutinib reached 19 months, showing durable efficacy in this relapsed/refractory population. Ongoing assessment for adverse events over time is important for BTK inhibitors, but pirtobrutinib continues to demonstrate a tolerable safety profile, with less than 3% discontinuation rate due to adverse events at 30 months.

Dr. Lamanna highlights this updated data for a non-covalent BTK inhibitor in patients failing standard therapies provides an exciting new treatment option for these patients. Having these agents on guidelines facilitates patient access and ability to implement sequencing strategies as the treatment landscape evolves.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.